Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.43 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.43 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30514179 | 1.00 | MAPT (0.43) | MAPTMEN1KMT2AMCOLN3PSIP1 | |
| SCHEMBL25865281 | 0.71 | BRD4 (0.49) | MEN1KMT2ATXNRD1ALDH1A1POLB | |
| SCHEMBL9024053 | 0.71 | ALDH1A1 (0.54) | MEN1KMT2ATDP1ALDH1A1POLB | |
| SCHEMBL14182008 | 0.70 | PDE10A (0.41) | MAPTMEN1KMT2AALDH1A1CYP1A2 | |
| Ammonia Solution, Strong SCHEMBL28382711 | 0.70 | TDP1 (0.48) | MAPTMEN1KMT2AMCOLN3PSIP1 | |
| SCHEMBL2070900 | 0.69 | KMT2A (0.57) | MAPTMEN1KMT2AMCOLN3PSIP1 | |
| SCHEMBL30595144 | 0.69 | KMT2A (0.57) | MAPTMEN1KMT2AMCOLN3PSIP1 | |
| SCHEMBL28246862 | 0.69 | NPC1 (0.50) | MAPTMEN1KMT2AMCOLN3PSIP1 | |
| SCHEMBL17778301 | 0.69 | PDE10A (0.40) | MAPTMEN1KMT2ATXNRD1ALDH1A1 | |
| SCHEMBL13240992 | 0.69 | PDE10A (0.40) | MAPTMEN1KMT2AALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250144093-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | AGIOS PHARMACEUTICALS, INC. | 2025-05-08 | — | — | US | disclosed |
| US-12133853-B2 | Pyruvate kinase activators for use in treating blood disorders | AGIOS PHARMACEUTICALS, INC. (US) | 2024-11-05 | — | — | US | disclosed |
| US-11872225-B2 | Pyruvate kinase modulators and use thereof | AGIOS PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| CN-117186119-A | Pyruvate kinase activators for the treatment of hematological disorders | 安吉奥斯医药品有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-111032046-B | Pyruvate kinase modulators and uses thereof | 安吉奥斯医药品有限公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-111032045-B | Pyruvate kinase activators for the treatment of hematological disorders | 安吉奥斯医药品有限公司 | 2023-08-15 | — | — | CN | disclosed |
| US-20230226055-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | AGIOS PHARMACEUTICALS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-11590132-B2 | Pyruvate kinase activators for use in treating blood disorders | AGIOS PHARMACEUTICALS, INC. (US) | 2023-02-28 | — | — | US | disclosed |
| EP-3668512-B1 | PYRUVATE KINASE MODULATORS AND USE THEREOF | AGIOS PHARMACEUTICALS INC (US) | 2023-02-15 | — | — | EP | disclosed |
| US-11464775-B2 | Pyruvate kinase modulators and use thereof | AGIOS PHARMACEUTICALS, INC. (US) | 2022-10-11 | — | — | US | disclosed |
| US-11040036-B2 | Pyruvate kinase activators for use in treating blood disorders | AGIOS PHARMACEUTICALS, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20210077490-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | AGIOS PHARMACEUTICALS, INC. | 2021-03-18 | — | — | US | disclosed |
| US-20200207785-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | PHARMARESOURCES (SHANGHAI) CO., LTD. (CN) | 2020-07-02 | — | — | US | disclosed |
| US-20200206225-A1 | PYRUVATE KINASE MODULATORS AND USE THEREOF | AGIOS PHARMACEUTICALS, INC. (US) | 2020-07-02 | — | — | US | disclosed |
| EP-3668512-A1 | PYRUVATE KINASE MODULATORS AND USE THEREOF | Agios Pharmaceuticals, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| EP-3668513-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | Agios Pharmaceuticals, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| CN-111032045-A | Pyruvate kinase activators for the treatment of blood disorders | 安吉奥斯医药品有限公司 | 2020-04-17 | — | — | CN | disclosed |
| CN-111032046-A | Pyruvate kinase modulators and uses thereof | 安吉奥斯医药品有限公司 | 2020-04-17 | — | — | CN | disclosed |
| WO-2019035865-A1 | PYRUVATE KINASE MODULATORS AND USE THEREOF | AGIOS PHARMACEUTICALS INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019035864-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | AGIOS PHARMACEUTICALS, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11872225-B2 | Pyruvate kinase modulators and use thereof | PDK1, PDK2, PDK4 | MAPT 3874/4885MEN1 2619/4885KMT2A 701/4885 |
| US-20200206225-A1 | PYRUVATE KINASE MODULATORS AND USE THEREOF | PDK1, PDK2, PDK4 | MAPT 3874/4885MEN1 2619/4885KMT2A 701/4885 |
| US-20230226055-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | PDK1, PDK2, PDK3 | MAPT 3891/4885MEN1 3725/4885KMT2A 560/4885 |
| US-11464775-B2 | Pyruvate kinase modulators and use thereof | PDK1, PDK2, PDK4 | MAPT 3874/4885MEN1 2619/4885KMT2A 701/4885 |
| US-11590132-B2 | Pyruvate kinase activators for use in treating blood disorders | PDK1, PDK2, PDK3 | MAPT 3891/4885MEN1 3725/4885KMT2A 560/4885 |
| US-20210077490-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | PDK1, PDK2, PDK3 | MAPT 3891/4885MEN1 3725/4885KMT2A 560/4885 |
| US-11040036-B2 | Pyruvate kinase activators for use in treating blood disorders | PDK1, PDK2, PDK3 | MAPT 3891/4885MEN1 3725/4885KMT2A 560/4885 |
| US-12133853-B2 | Pyruvate kinase activators for use in treating blood disorders | PDK1, PDK2, PDK3 | MAPT 3891/4885MEN1 3725/4885KMT2A 560/4885 |
| US-20200207785-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | PDK1, PDK2, PDK3 | MAPT 3805/4885MEN1 3842/4885KMT2A 606/4885 |
| US-20250144093-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | PDK1, PDK2, PDK3 | MAPT 3891/4885MEN1 3725/4885KMT2A 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.